Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
11.30
-0.04 (-0.35%)
Jan 17, 2025, 4:00 PM EST - Market closed
Viatris Revenue
Viatris had revenue of $3.75B in the quarter ending September 30, 2024, a decrease of -4.84%. This brings the company's revenue in the last twelve months to $15.05B, down -2.70% year-over-year. In the year 2023, Viatris had annual revenue of $15.43B, down -5.14%.
Revenue (ttm)
$15.05B
Revenue Growth
-2.70%
P/S Ratio
0.90
Revenue / Employee
$396,013
Employees
38,000
Market Cap
13.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
| Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
| Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
| Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
| Dec 31, 2019 | 11.50B | 66.60M | 0.58% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
VTRS News
- 6 days ago - Viatris Inc. (VTRS) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 13 days ago - Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 14 days ago - Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes - Seeking Alpha
- 4 weeks ago - US FDA sends warning letter to Viatris over India manufacturing facility - Reuters
- 4 weeks ago - Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology - PRNewsWire
- 7 weeks ago - Mapi Pharma is Seeking New Depot Product Partnerships - GlobeNewsWire
- 2 months ago - UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe - Reuters
- 2 months ago - Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript) - Seeking Alpha